Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/20/2025 | $35.00 | Outperform | Wedbush |
2/4/2025 | $19.00 | Outperform | Wolfe Research |
12/16/2024 | $30.00 | Buy | H.C. Wainwright |
11/5/2024 | $34.00 | Buy | Rodman & Renshaw |
10/8/2024 | $45.00 | Buy | Guggenheim |
10/8/2024 | $40.00 | Overweight | Morgan Stanley |
10/8/2024 | $35.00 | Buy | Jefferies |
10/8/2024 | $27.00 | Buy | Citigroup |
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4). The Committee granted a non-qualified stock option to purchase
WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
3 - Zenas BioPharma, Inc. (0001953926) (Issuer)
DEFA14A - Zenas BioPharma, Inc. (0001953926) (Filer)
DEF 14A - Zenas BioPharma, Inc. (0001953926) (Filer)
SCHEDULE 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00
Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00
H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00